Clarissa Serodio da Rocha Baldotto

Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

BackgroundSavolitinib is an oral, potent, highly selective MET–tyrosine kinase inhibitor (TKI). Combination therapy with savolitinib and osimertinib, an epidermal growth factor receptor (EGFR)–TKI, has shown activity in patients with EGFR-mutated, advanced non–small-cell lung can...

Collaborative intelligence for sustainable and patient-partnered clinical research

This strategic perspective proposes a governance-oriented conceptual model for sustainable, patient-partnered oncology research in Brazil, with regional relevance for Latin America and broader global implications. It argues that strengthening clinical research ecosystems, current...